This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Comtess, entacapone
Description: Comtan (Entacapone) inhibits peripheral catechol-O-methyltransferase (COMT), which breaks down levodopa. When used with an aromatic amino acid decarboxylase inhibitor (to inhibit the other major enzyme metabolizing levodopa peripherally), plasma levels of levodopa are greater and more sustained after administration of levodopa. The effect of Comtan on central COMT is unknown.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
In 1996, Sandoz (which then merged with Ciba to become Novartis) licensed Comtan from Orion Pharma and has exclusive marketing rights except in certain Scandinavian/Baltic/Eastern European countries, the UK, Ireland, and Germany.
BioMedTracker groups Stalevo and Comtan revenue together under Stalevo.
Partners: Orion Corporation
Pink Sheet Comtan Clinical Protocols
Pink Sheet Comtan Clinical Development
Additional information available to subscribers only: